No abstract available
Keywords:
Canakinumab; diabetes; drug therapy; metabolic inflammation; nonalcoholic fatty liver disease.
MeSH terms
-
Animals
-
Humans
-
Interleukin-1alpha / antagonists & inhibitors*
-
Interleukin-1alpha / metabolism
-
Interleukin-1beta / antagonists & inhibitors*
-
Interleukin-1beta / metabolism
-
Non-alcoholic Fatty Liver Disease / drug therapy*
-
Non-alcoholic Fatty Liver Disease / physiopathology
Substances
-
Interleukin-1alpha
-
Interleukin-1beta